We reported that serum and tumor from a hypoglycemic patient with a fibrosarcoma contained insulinlike growth factor II (IGF-II), mostly in a large molecular form designated "big IGF-ll." We now describe two additional patients with non-islet-cell tumor with hypoglycemia (NICTH) whose sera contained big IGF-ll. Removal of the tumor eliminated most of the big IGF-ll from the sera of two patients. Because specific IGF-binding proteins modify the bioactivity of IGFs, the sizes of the endogenous IGF-binding protein complexes were determined after neutral gel ifitration through Sephadex G-200. Normally about 75% of IGFs are carried as a ternary complex of 150 kDa consisting of IGF, a growth hormone (GH)-dependent IGF-binding protein, and an acidlabile complexing component. The three patients with NICTH completely lacked the 150-kDa complex. IGF-U was present as a 60-kDa complex with variable contributions of smaller complexes. In the immediate postoperative period, a 110-kDa complex appeared rather than the expected 150-kDa complex.
Abnormal IGF-ll binding may be important in NICTH because the 150-kDa complexes cross the capillary membrane poorly. The smaller complexes present in our patients' sera would be expected to enter interstitial fluid readily, and a 4-to 5-fold increase in the fraction of IGFs reaching the target cells would result.
Many mesenchymal tumors express the insulin-like growth factor II (IGF-II) gene (1) (2) (3) (4) (5) (6) (7) . Increased concentrations of IGF-II have been detected in some of these tumors (3, 6, 7) , and explants of one tumor have released IGF-II into the medium (7) . It has been suspected that secretion of IGF-II by certain large mesenchymal tumors might be related to the syndrome of non-islet-cell tumor hypoglycemia (NICTH), although attempts to detect such peptides in serum with relatively nonspecific insulin bioassays have given conflicting results (8, 9) . Increased concentrations of serum IGF-II-like peptides were found by radioreceptor assay in some cases of NICTH (10, 11) . Even when elevated, the increases in IGF-II concentrations were often small and could not be confirmed with a number of assay methods by Widmer et al. (12) . Recently, Daughaday et al. (6) described a case of a woman with a fibrosarcoma (originally identified as a leiomyosarcoma) with hypoglycemia, whose tumor contained greatly increased IGF-II mRNA and IGF-II peptide. After acid gel filtration, most of the serum and tumor IGF-II was present as big IGF-II. Because the severity of the metabolic symptoms of these patients with NICTH is not easily explained by the modest degree of increase of IGF-II, we undertook studies of the association of endogenous IGF-II to serum binding proteins in three cases of mesenchymal tumors with clinically severe hypoglycemia.
METHODS
Source of Sera. Case 1. Sera from a 67-year-old woman with severe symptomatic hypoglycemia and a large recurrent sarcoma of her thorax were kindly provided by Mary Ann Emanuele of Loyola University School ofMedicine, Chicago. The tumor was originally considered to be a leiomyosarcoma, but subsequently the diagnosis was changed to a fibrosarcoma. A second serum sample was obtained weeks postoperatively, at which time her hypoglycemia was in remission. A report describing this patient has been published (6).
Case 2. Serum from a 19-year-old young man with severe hypoglycemia and a hemangiopericytoma. A second serum was obtained after removal ofthe tumor while the patient was in remission from his hypoglycemia. These sera were collected by Allen Eisman of University of Kansas School of Medicine and kindly provided by Kenneth Polonsky of the University of Chicago.
Case 3. Serum was obtained from a 71-year-old woman with severe symptomatic hypoglycemia and a large leiomyosarcoma. A second serum was obtained a week after operation while the patient was euglycemic. These sera were kindly provided by Mark H. Greene of Peoria, AZ.
Chromatographic Methods. Acid gel filtration was used to determine IGF-II size heterogeneity. Two milliliters of serum was acidified with 0.2 ml of 4 M acetic acid and passed through a 2.5 x 98 cm column of Bio-Gel P-60 (Bio-Rad) in 0.5 M acetic acid/0.075 M NaCl at room temperature. The flow rate was 0.31 ml/min, and 5-ml fractions were collected. This column is able to separate 7.5-kDa IGF-I and 7.5-kDa IGF-II nearly completely from each other and from the serum binding proteins (6) .
Neutral gel filtration was used to determine the pattern of serum binding of IGF-II. Serum (1 ml) was passed through a 44 x 1.4 cm column of Sephadex G-200 in 0.05 M sodium diphosphate/0.15 M NaCl/0.02% NaN2, pH 7.4, at room temperature. The flow rate was 0.32 ml/min and 1.6-ml fractions were collected.
Assay Methods. Serum levels of IGF-I and -II were determined after acidic ethanol extraction by RIA (13 Abbreviations: IGF, insulin-like growth factor; NICTH, nonislet-cell tumor hypoglycemia; GH, growth hormone.
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Laboratories, Indianapolis) was iodinated. Homogenous IGF-II isolated from bovine serum was used as the standard in the RIA.
Fractions obtained from the Bio-Gel P-60 acid gel column were assayed directly. All fractions from the neutral Sephadex G-200 column were subjected to acidic ethanol extraction before assay to avoid interference from serum binding proteins.
RESULTS
The concentration of IGF-I in sera of these patients after acidic ethanol extraction was markedly suppressed. After an operation in cases 1 and 3, there was a 3-to 4-fold rise in IGF-I. In case 3, where considerable tumor was evidently left behind, the rise in IGF-I was less than 2-fold. Table 1 presents the results of IGF-II assays of the sera of these patients. Assays performed on acidic ethanol extracts of serum were normal in all cases. When these sera were subjected to Bio-Gel P-60 acid gel filtration and the sum ofthe IGF-I1 concentrations was determined, it was noted that there was a substantial increment in IGF-Il, suggesting that acidic ethanol did not recover all the IGF-II in the large molecular form ("big IGF-II").
With P-60 acid gel filtration ofnormal serum, 7.5-kDa IGF-II was eluted slightly after the column volume shown as the dashed line in Fig. 1 . Cytochrome c (13 kDa) on this column was eluted with a peak at about tube 74. The preoperative sera from cases 1, 2, and 3 had most (70-93%) of the immunoreactive IGF-II as a broad irregular peak whose estimated size was from 15 to 7.5 kDa (Fig. 1) . After the operation, 93% of the IGF-II from case 1 serum and 67% of the IGF-I1 from case 2 serum was of the 7.5-kDa size. There was an increase in the 7.5-kDa IGF-II in the serum of case 3 after the operation and a persistence of big IGF-I1 with a much more restricted size heterogeneity than before the operation.
The results of Sephadex G-200 neutral gel filtration of a serum from a normal young woman are shown in Fig. 2 . The optical density curve has the expected triple peaks at 280-,um absorbance representing macroglobulin, gamma globulin (160 kDa), and serum albumin (67 kDa). These proteins provide useful internal calibrations ofthe columns. The major IGF-containing complex of normal serum was eluted slightly after the IgG peak and will be referred to as the 150-kDa peak. Not seen in this normal serum but present in some of the sera from patients with NICTH is a peak eluted in a position intermediate between the IgG and albumin peaks. This will be referred to as the 110-kDa peak. The second most prominent portion of IGF-II complexes in normal serum was eluted slightly later than albumin and is referred to as the 60-kDa peak. The normal serum and the sera from patients with doublet with a molecular mass of 47-53 kDa that is growth hormone (GH) dependent (designated BPGH) (18, 19) . When this binding protein is occupied by an IGF molecule, it can complex with an acid-labile glycoprotein, designated CP, of 84-86 kDa to form the 150-kDa complex (20) . Normal serum also contains a small concentration of complexes with a molecular mass of "120 kDa. Hardouin et al. (21) have suggested that this complex includes a deglycosylated form of BPGH with a molecular mass of "'30 kDa associated with IGF and CP.
The second distinct type of IGF binding protein of serum is GH independent, nonglycosylated, and unreactive with CP. This binding protein, BPAF, is identical to the 28-kDa binding protein isolated from amniotic fluid (22) . BPAF carries little IGF in serum from normal and hypopituitary individuals (21) . BPkF exhibits a marked circadian pattern of concentration with highest levels reached at night and is markedly affected by changes in glucose metabolism. The concentration of this binding protein rises abruptly during hypoglycemia (23) . These properties are not shared by the BPGH. The dominant 60-kDa complex found in sera ofpatients with NICTH reported here probably consists of IGF-II and BPGH.
These results suggest that the secretion of CP in these subjects is markedly suppressed. In addition to the 60-kDa complex, These could represent binding by BPkF or by deglycosylated BPGH. Distinguishing between these two species can only be done with specific antibodies unavailable to us.
The changes in the pattern of serum binding of IGF-II in cases 2 and 3, which occurred after surgery, were unexpected. The proportion of IGF-II present as 60-kDa complexes decreased, and complexes of roughly 110 kDa appeared that were eluted between the albumin and gamma globulin peaks. This suggests participation of CP in a complex with partial deglycosylated CP or BPGH-
The pathophysiology of NICTH is complex. GH acts on target tissues to promote synthesis and secretion of IGF-I, IGF-II, GHBp, and CP, primarily from the liver. In simple GH deficiency there is marked decrease in serum IGF-I, BPGH, and CP with a smaller decrease in IGF-II. The tumors associated with NICTH that have been studied secrete IGF-II, and we suspect that they also secrete BPGH without CP (Fig. 3) . IGF-II acting on the hypothalamus and pituitary would explain the GH deficiency of these patients (6, 7), which would increase sensitivity to insulin-like peptides and explain at least in part the abnormalities in serum binding of IGF-II, which we report here.
The changes in serum binding may be important in understanding the major physiologic consequences of modest elevations of serum IGF-II in NICTH. About 75% of IGFs in normal serum are carried in the 150-kDa complexes and only 25% as small complexes. Binoux and Hossenlopp (24) found that lymph contained about 20o as much IGF-I and IGF-II as serum and that only 7% of the IGF in lymph was present as the 150-kDa complex and the remainder as small complexes. They concluded that only the small complexes can easily traverse the endothelial barrier. Because nearly all of the IGF complexes in the serum of patients with NICTH are small, the concentration of IGF-II in lymph may be as much as 4-fold higher than would occur with normal serum binding.
